TickerFacts.

Entera Bio Ltd. (ENTX): Gross Profit

Annual figures by period end, from SEC filings.

$0
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
$198.0K2020-12-31: $65.0K2021-12-31: $198.0K2022-12-31: $33.0K2023-12-31: $02024-12-31: $9.0K2025-12-31: $0$0
2020-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$0-100.0%2026-03-27, From 2025-01-01
2024-12-31$9.0Kn/a2026-03-27, From 2024-01-01
2023-12-31$0-100.0%2025-03-28, From 2023-01-01
2022-12-31$33.0K-83.3%2024-03-08, From 2022-01-01
2021-12-31$198.0K+204.6%2023-03-31, From 2021-01-01
2020-12-31$65.0Kn/a2022-03-08, From 2020-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
Entera Bio Ltd. (ENTX)2025-12-31$0-100.0%
Zivo Bioscience, Inc. (ZIVO)2024-12-31$49.0K+321.6%
Creative Medical Technology Holdings, Inc. (CELZ)2025-12-31$3.8K-42.3%
Pluri Inc. (PLUR)2026-06-30$453.0K-30.7%
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31-$2.65Mn/m
Outlook Therapeutics, Inc. (OTLK)2025-09-30$57.2Kn/a
Humacyte, Inc. (HUMA)2025-12-31-$7.66Mn/a
Dyadic International Inc (DYAI)2025-12-31$770.5K-66.5%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$4.27M+13.0%

Compare ENTX, ZIVO, CELZ, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗